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Summary
Use and abuse of novel psychoactive substances (NPS) remains a public health and law enforcement challenge across Eu-
rope and bordering countries. Increasingly NPS detected on the drug market include those with legitimate use as medicines 
or active pharmaceutical ingredients in medicines. This Short Communication wishes to draw attention to reports on the 
concerning upward trend of intravenous (IV) use of eyedrops containing tropicamide by problematic opiate users. Since 
2013, trends of diversion by IV route are identified as a new phenomenon in Europe. Sales in Russia and Eastern Europe 
in particular have increased significantly in the past five years. Key indicators of suspected misuse include online interest 
particularly from Russia, Ukraine and other Eastern European countries, and pharmacovigilance and clinical alerts from 
Turkey , Italy, France, Georgia, Russia, Tajikistan, and Kazakhstan. Tropicamide is injected as secondary to the primary 
opiate addiction, and reportedly occurs as self-sufficient means to get high amongst opiate injectors when primary opiates 
such as heroin are not available, and as poly-substitute to further enhance the opiate effect and manage heroin (and to a 
lesser extent methadone) withdrawals . Anecdotally, injection of tropicamide is known as the ‘seven monther’ in relation 
to the length of time it takes to kill the user. The diversion of tropicamide is high risk, concentrated within problematic 
drug user networks, and conducted by individuals who may not be engaging with social and medical systems. Aside from 
dependence and physical/psychiatric harms, the risk pertaining to this injecting phenomenon as potential contribution 
toward virus transmission (HIV, Hepatitis C) within injecting networks are present. The Short Communication presents 
extant literature on the topic, and discusses implications for drug policy and service delivery. 
Key Words: Novel Psychoactive Substance; Tropicamide; eyedrops
Use and abuse of novel psychoactive substances 
(NPS) remains a public health and law enforcement 
challenge across Europe and bordering countries [18]. 
NPS notified to the EU Early Warning System (EWS) 
continue to rise, with the World Health Organisation 
reporting on a global rise of 55% in 2015. The United 
Nations Office on Drugs and Crime (UNODC) and 
the European Union (EU) define NPS as “substances 
of abuse, either in a pure form or a preparation, that 
are not controlled by the 1961 Single Convention on 
Narcotic Drugs or the 1971 Convention on Psycho-
tropic Substances, but which may pose a public health 
threat” [17]. Of note is that UNODC extends the con-
cept of NPS to emerging drug trends, not necessar-
ily new designer drugs, but also substances recently 
available. The EU legal framework of Council De-
cision 2005/387/JHA also defines NPS as including 
human or veterinary medicinal products. Increasingly 
NPS detected on the drug market include those with 
legitimate use as medicines or active pharmaceutical 
ingredients in medicines. The European Medicines 
Agency (EMA) and the European Monitoring Cen-
tre for Drugs and Drug Addiction (EMCDDA) cur-
rently exchange information around abuse of medici-
nal products. Recent examples include those notified 
under the Council Decision and detected by the EU-
EWS (phenibut, gabapentin, cafentanyil, pregabalin, 
etaqualone, zopiklone and tropicamide) [6-7]. 
This Short Communication wishes to draw at-
tention to reports on a concerning upward trend of 
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intravenous (IV) use of eyedrops containing tropi-
camide by problematic opiate users. Tropicamide is 
a mydriatic atropenic ophthalmic drug indicated for 
therapeutic or diagnostic procedures to dilate the pu-
pils [12]. It is administered for very short-term expo-
sure periods, at starting doses of one drop (150 μg of 
tropicamide) and not exceeding 3 ml of the solution. 
Effects at higher dosages include visual hallucina-
tions, confused states, sedation and delirium [1, 9]. 
Since 2013, trends of diversion by IV route are iden-
tified as a new phenomenon in Europe. Sales in Rus-
sia and Eastern Europe in particular have increased 
significantly in the past five years [13-14, 19]. Key 
indicators of suspected misuse include online interest 
particularly from Russia, Ukraine and other Eastern 
European countries [3, 11], and pharmacovigilance 
and clinical alerts from Turkey [5], Italy [3, 15], 
France [11], Georgia [2], Russia [3, 19], Tajikistan 
[8, 10, 20], and Kazakhstan [13-14]. 
Tropicamide is injected as secondary to the pri-
mary opiate addiction, and reportedly occurs as self-
sufficient means to get high amongst opiate injectors 
when primary opiates such as heroin are not availa-
ble, and as poly-substitute to further enhance the opi-
ate effect, and to manage heroin (and to a lesser extent 
methadone) withdrawals [2, 4, 5, 10, 15, 19, 20]. Ad-
ditional factors supporting the rapid diffusion of this 
new injecting phenomenon within Russia and Eastern 
Europe are observed by Bersani and colleagues [4] 
in their mini-review and centre on rapid onset of ef-
fect, ease of availability and low cost, and visibility of 
user interest and experiences online. Prilutskaya and 
Kuliev [14] also speculate that tropicamide’s popular-
ity is due to its readiness for injection, in contrast to 
other pharmacy sourced medicinal products such as 
codeine, ephedrine and desomorphine which require 
some level of home preparation prior to injecting (for 
example ‘Krokodil’, see [18]). Tropicamide eyedrops 
can easily be bought online and in pharmacies [4]. 
Acute intoxication characterised by hallucina-
tions (‘open eye dreams’), dizziness, hyperthermia, 
tremors, convulsions, suicidal ideation, psychomotor 
agitation, tachycardia and psychosis, diagnosis of an-
ticholinergic syndrome and adverse chronic health 
problems (severe weight loss, cognitive impairment, 
cardiovascular toxicity, renal or liver failure, post 
injection purulent soft tissue complications, viral 
transmission and both physical and psychological 
dependence) are reported [3-5, 11, 13-15]. Anecdo-
tally, injection of tropicamide is known as the ‘seven 
monther’ in relation to the length of time it takes to 
kill the user [3]. In the past five years, fatalities in 
Russia have been reported in the media and on drug 
fora [3, 4, 16]. 
The diversion of tropicamide is high risk, con-
centrated within problematic drug user networks, and 
conducted by individuals who may not be engaging 
with social and medical systems [11]. Aside from 
dependence and physical/psychiatric harms, the risk 
pertaining to this injecting phenomenon as potential 
contribution toward virus transmission (HIV, Hepati-
tis C) within injecting networks are present. Given the 
fluctuations in opiate and diverted opioid availability 
in regions where tropicamide is used, this remains 
concerning, even though primary tropicamide abuse 
is not commonly reported, and it appears situated 
within poly substance use as ‘top up’ drug. Tropi-
camide’s craving’s specificity appears to get lost in 
addictive processes, with poly-substance abuse of 
tropicamide in opiate dependency going far beyond 
cross-tolerance mechanisms.
The rising reports in Russia and Eastern Europe, 
and more recently in France and Italy, of tropicamide 
abuse by known injecting networks of drug users 
therefore warrants a careful response, instigated by 
country and EU wide risk assessment. Gauging the 
public health risks within countries experiencing this 
injecting phenomenon is difficult, and yet are neces-
sary to underpin further development and coverage 
of pharmaco and addicto-vigilance regulatory sys-
tems. National early warning systems are uniquely 
positioned to identify early and continued levels of 
abuse of this diverted medicinal product, particularly 
within existing problem drug user networks. Given 
the cross over between pharmacy and street supply 
of tropicamide, a multi-disciplinary approach to inte-
grate regulation, enforcement, and surveillance of di-
version and suspected abuse is imperative to monitor 
and respond to this type of medicinal diversion. Rou-
tine forensic detection, monitoring and surveillance 
of a broad reach of potential information sources both 
inside and outside countries experiencing this trend 
are therefore necessary. For countries experiencing 
this form of medicinal diversion, training of health, 
pharmacy and medical professionals in the detection 
of suspected abuse and appropriate clinical respons-
es for those experiencing tropicamide related health 
problems and dependence are warranted [3, 5, 11, 
14-15]. Research efforts can assist in the garnering 
of understanding tropicamide as relatively new drug 
situated within problem drug user populations, and 
can help support the development of targeted preven-
tion and harm reduction initiatives. Within the wider 
EU domain, the regular surveillance of online drug 
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fora and trend interest in tropicamide (and other phar-
maceuticals with abuse liability) should continue. 
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